AKT1 and neoplasm: Capivasertib is known to have antitumor activity against PIK3CA/AKT-mutated tumors,20,43,44 and therefore we tested whether this drug would enhance the efficacy of CAR T cell therapy in the context of tumor-bearing PIK3CA/AKT pathway mutations.